CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
German cohort on Sofosbuvir based therapy for HIV/HCV- and HCV-infection (GECCO) – Patients on opioid substitution therapy (OST) respond as well as non-OST patients
DOI 10.1055/s-0035-1559169
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Christensen, P Ingiliz, D Hüppe, T Lutz, K Simon, K Schewe, C Schwarze-Zander, H Busch, A Baumgarten, G Schmutz, S Mauss
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Sofosbuvir (SOF) was approved in Europe in January 2014. However, outcomes of SOF based therapy in patients on OST in comparison to NON-OST were not systematically studied. Here, we present corresponding real-life data on SOF-based treatments from Germany. Methods: Ongoing multicenter cohort on HCV patients who were started on the following HCV treatments: SOF/Ribavirin (RBV), SOF/Daclatasvir (DCV), SOF/…
Zitieren
Zitierempfehlung
S Christensen, P Ingiliz, D Hüppe, T Lutz, K Simon, K Schewe, C Schwarze-Zander, H Busch, A Baumgarten, G Schmutz, S Mauss (2015) German cohort on Sofosbuvir based therapy for HIV/HCV- and HCV-infection (GECCO) – Patients on opioid substitution therapy (OST) respond as well as non-OST patients. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0035-1559169
Mit CareLit weiterarbeiten